{"generic":"Levofloxacin","drugs":["Iquix","Levaquin","Levofloxacin","Quixin"],"mono":[{"id":"924104-s-0","title":"Generic Names","mono":"Levofloxacin"},{"id":"924104-s-1","title":"Dosing and Indications","sub":[{"id":"924104-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute bacterial exacerbation of chronic bronchitis:<\/b> 500 mg IV\/orally every 24 hours for 7 days<\/li><li><b>Bacteremia associated with intravascular line:<\/b> (due to Chryseobacterium (Flavobacterium) species) 750 mg IV every 24 hours<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution) 1 to 2 drops in the affected eye(s) every 2 hours while awake (MAX, 8 times\/day) on days 1 and 2; 1 to 2 drops every 4 hours while awake (MAX 4 times\/day) on days 3 through 7<\/li><li><b>Bacterial prostatitis, chronic:<\/b> 500 mg IV\/orally every 24 hours for 28 days<\/li><li><b>Bacterial sinusitis, acute:<\/b> 750 mg IV\/orally every 24 hours for 5 days; OR 500 mg IV\/orally every 24 hours for 10 to 14 days<\/li><li><b>Bacterial sinusitis, acute:<\/b> Beta-lactam allergy, second-line: 500 mg IV\/orally daily (guideline dosing)<\/li><li><b>Chlamydial infection:<\/b> 500 mg orally once daily for 7 days<\/li><li><b>Community acquired pneumonia:<\/b> 500 mg IV\/orally every 24 hours for 7 to 14 days OR 750 mg IV\/orally every 24 hours for 5 days<\/li><li><b>Complicated urinary tract infection:<\/b> 250 mg IV\/orally every 24 hours for 10 days for infections due to Enterococcus faecalis, Enterococcus cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa<\/li><li><b>Complicated urinary tract infection:<\/b> 750 mg IV\/orally every 24 hours for 5 days for infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis<\/li><li><b>Corneal ulcer:<\/b> (1.5% ophthalmic solution) Days 1 through 3, 1 to 2 drops every 30 minutes to 2 hours while awake and 4 hours and 6 hours after retiring; day 4 through treatment end, 1 to 2 drops every 1 to 4 hours while awake<\/li><li><b>Epididymitis:<\/b> Caused by enteric organisms or with negative gonococcal nucleic acid amplification test: 500 mg orally once daily for 10 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> Uncomplicated: 500 mg IV\/orally every 24 hours for 7 to 10 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> Complicated: 750 mg IV\/orally every 24 hours for 7 to 14 days<\/li><li><b>Inhalational anthrax, Postexposure; Prophylaxis:<\/b> 500 mg IV\/orally every 24 hours for 60 days<\/li><li><b>Nongonococcal urethritis:<\/b> 500 mg orally once daily for 7 days<\/li><li><b>Nosocomial pneumonia:<\/b> 750 mg IV\/orally every 24 hours for 7 to 14 days<\/li><li><b>Plague:<\/b> 500 mg IV\/orally once every 24 hours for 10 to 14 days<\/li><li><b>Pyelonephritis, acute:<\/b> 250 mg IV\/orally every 24 hours for 10 days for infections due to E coli (manufacturer dosing)<\/li><li><b>Pyelonephritis, acute:<\/b> 750 mg IV\/orally every 24 hours for 5 days for infections due to E coli including cases with concurrent bacteremia (manufacturer dosing)<\/li><li><b>Pyelonephritis, acute:<\/b> 750 mg orally once daily for 5 days (guideline dosing)<\/li><li><b>Traveler's diarrhea:<\/b> 500 mg orally once daily for 1 to 3 days<\/li><li><b>Tuberculosis:<\/b> 500 to 1000 mg IV\/orally once daily<\/li><li><b>Uncomplicated urinary tract infection:<\/b> 250 mg IV\/orally every 24 hours for 3 days<\/li><\/ul>"},{"id":"924104-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>(oral and IV) safety and efficacy in children under 6 months of age have not been established<\/li><li>(ophthalmic) safety and efficacy of the 0.5% solution in children less than 1 year of age and of the 1.5% solution in children under 6 years of age have not been established<\/li><li><b>Bacterial conjunctivitis:<\/b> (0.5% ophthalmic solution) 1 year or older; 1 to 2 drops in the affected eye(s) every 2 hours while awake (MAX, 8 times\/day) on days 1 and 2; 1 to 2 drops every 4 hours while awake (MAX 4 times\/day) on days 3 through 7<\/li><li><b>Community acquired pneumonia:<\/b> (6 months to 5 years) 16 to 20 mg\/kg\/day IV\/orally in 2 divided doses every 12 hours for 10 days; MAX 750 mg\/day. Duration may be shorter for outpatient treatment of mild infections and longer for resistant or complicated infections (guideline dosing)<\/li><li><b>Community acquired pneumonia:<\/b> (5 to 16 years of age) 8 to 10 mg\/kg\/day IV\/orally once daily; for Mycoplasma pneumoniae, 16 to 20 mg\/kg\/day IV in 2 divided doses every 12 hours; MAX 750 mg\/day. Duration is 10 days, but may be shorter for outpatient treatment of mild infections and longer for resistant or complicated infections (guideline dosing).<\/li><li><b>Community acquired pneumonia:<\/b> (Adolescents with skeletal maturity) 500 mg orally once daily for Mycoplasma pneumoniae, Chlamydia trachomatis, or Chlamydophila pneumoniae. Duration is 10 days, but may be shorter for outpatient treatment of mild infections and longer for resistant or complicated infections (guideline dosing).<\/li><li><b>Corneal ulcer:<\/b> (1.5% ophthalmic solution, 6 years or older) Days 1 through 3, 1 to 2 drops every 30 minutes to 2 hours while awake and 4 hours and 6 hours after retiring; day 4 through treatment end, 1 to 2 drops every 1 to 4 hours while awake<\/li><li><b>Inhalational anthrax, Postexposure; Prophylaxis:<\/b> (6 months or older, greater than 50 kg) 500 mg IV\/orally every 24 hours for 60 days<\/li><li><b>Inhalational anthrax, Postexposure; Prophylaxis:<\/b> (6 months or older, less than 50 kg) 8 mg\/kg IV\/orally every 12 hours for 60 days; MAX 250 mg\/dose<\/li><li><b>Plague:<\/b> (6 months or older, greater than 50 kg) 500 mg IV\/orally once every 24 hours for 10 to 14 days<\/li><li><b>Plague:<\/b> (6 months or older, less than 50 kg) 8 mg\/kg IV\/orally every 12 hours for 10 to 14 days; MAX 250 mg\/dose<\/li><\/ul>"},{"id":"924104-s-1-6","title":"Dose Adjustments","mono":"<ul><li>renal impairment (CrCl 50 mL\/min or greater) no dose adjustment necessary<\/li><li><b>renal impairment:<\/b> (if normal adult dose is 750 mg every 24 hours) CrCl 20 to 49 mL\/min, 750 mg every 48 hours; CrCl 10 to 19 mL\/min or hemodialysis\/chronic ambulatory peritoneal dialysis (CAPD), 750 mg initially then 500 mg every 48 hours<\/li><li><b>renal impairment:<\/b> (if normal adult dose is 500 mg every 24 hours) CrCl 20 to 49 mL\/min, 500 mg initially then 250 mg every 24 hours; CrCl 10 to 19 mL\/min or hemodialysis\/chronic ambulatory peritoneal dialysis (CAPD), 500 mg initially then 250 mg every 48 hours<\/li><li><b>renal impairment:<\/b> (if normal adult dose is 250 mg every 24 hours) CrCl 20 mL\/min and greater, no adjustment necessary; CrCl 10 to 19 mL\/min, 250 mg every 48 hours (no dose adjustment necessary if treating uncomplicated UTI)<\/li><li>renal impairment (CrCl less than 50 mL\/min) 500 mg initially then 250 mg every 48 hours; alternatively, (CrCl less than 30 mL.min) 750 to 1000 mg 3 times per week<\/li><li>hemodialysis, 750 to 1000 mg three times per week<\/li><\/ul>"},{"id":"924104-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute bacterial exacerbation of chronic bronchitis<\/li><li>Bacterial conjunctivitis<\/li><li>Bacterial prostatitis, chronic<\/li><li>Bacterial sinusitis, acute<\/li><li>Community acquired pneumonia<\/li><li>Complicated urinary tract infection<\/li><li>Corneal ulcer<\/li><li>Infection of skin AND\/OR subcutaneous tissue<\/li><li>Inhalational anthrax, Postexposure; Prophylaxis<\/li><li>Nosocomial pneumonia<\/li><li>Plague<\/li><li>Pyelonephritis, acute<\/li><li>Uncomplicated urinary tract infection<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Acute otitis media, Recurrent and\/or persistent<\/li><li>Bacteremia associated with intravascular line<\/li><li>Bacterial infectious disease; Prophylaxis - Febrile neutropenia, Chemotherapy-induced<\/li><li>Chlamydial infection<\/li><li>Epididymitis<\/li><li>Infectious enteritis<\/li><li>Nongonococcal urethritis<\/li><li>Postoperative infection<\/li><li>Traveler's diarrhea<\/li><li>Tuberculosis<\/li><\/ul>"}]},{"id":"924104-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Solution)<\/b><br\/>Fluoroquinolones, including levofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplants. Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.<br\/><\/li><li><b>Oral (Tablet; Solution)<\/b><br\/>Fluoroquinolones, including levofloxacin, are associated with an increased risk of tendinitis and tendon rupture in all ages. Risk further increases with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplants. Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.<br\/><\/li><\/ul>"},{"id":"924104-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924104-s-3-9","title":"Contraindications","mono":"hypersensitivity to levofloxacin, or any other quinolone antibiotics, including ofloxacin or any product components<br\/>"},{"id":"924104-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- QT interval prolongation, including rare cases of torsade de pointes, has been reported; avoid use with known QT prolongation, uncorrected hypokalemia, and with Class IA (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmic agents<\/li><li>Dermatologic:<\/li><li>-- moderate or severe phototoxicity may occur; avoid excessive exposure to sunlight or UV light and discontinue if phototoxicity occurs<\/li><li>Endocrine and Metabolic:<\/li><li>-- diabetic patients, especially patients receiving oral hypoglycemic agents or insulin may experience hyperglycemia or hypoglycemia; monitoring recommended; discontinue if hypoglycemia occurs<\/li><li>Hepatic:<\/li><li>-- hepatotoxicity, including acute hepatitis and fatal cases, has been reported with higher incidence in patients 65 years and older; discontinue if signs and symptoms of hepatitis occur<\/li><li>Immunologic:<\/li><li>-- serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, have been reported; discontinue at first occurrence of skin rash, jaundice, or any other sign of hypersensitivity<\/li><li>Musculoskeletal:<\/li><li>-- avoid use in patients with myasthenia gravis as muscle weakness may be exacerbated; ventilatory support requirement and death have been reported<\/li><li>-- tendinitis and tendon rupture risk increase especially with age over 60 years, concomitant steroid therapy, and kidney, heart, or lung transplant; discontinue at first sign of tendon pain, swelling, or inflammation<\/li><li>-- patients with history of tendon disorders, such as rheumatoid arthritis, may be at greater risk for tendon rupture<\/li><li>Neurologic:<\/li><li>-- use caution in patients with known or suspected CNS disorders, such as severe cerebral arteriosclerosis or epilepsy, due to risk of seizures or toxic psychoses; discontinue if occurs<\/li><li>-- CNS effects such as convulsions, toxic psychoses, increased intracranial pressure (including pseudotumor cerebri) have been reported; discontinue with any occurrence<\/li><li>-- peripheral neuropathy has been reported with oral and injectable fluoroquinolones and may occur any time during therapy and persist for months to years or become permanent even after discontinuation; if symptoms occur, discontinue and switch to a non-fluoroquinolone unless benefit outweighs risk<\/li><li>Ophthalmic:<\/li><li>-- prolonged use of ophthalmic solution may cause overgrowth of nonsusceptible organisms<\/li><li>Renal:<\/li><li>-- use caution in patients with renal dysfunction or renal failure due to risk of seizures and tendon rupture<\/li><li>Other:<\/li><li>-- elderly patients may be at greater risk for QT prolongation<\/li><li>-- pediatric patients may develop musculoskeletal disorders, including arthralgia, arthritis, tendinopathy, and gait abnormality<\/li><li>-- strenuous physical activity may increase risk of tendon rupture<\/li><\/ul>"},{"id":"924104-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924104-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"924104-s-4","title":"Drug Interactions","sub":[{"id":"924104-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"924104-s-4-14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Acecainide (theoretical)<\/li><li>Acetohexamide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Benfluorex (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (probable)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (probable)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gliclazide (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Gliquidone (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Moricizine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rasagiline (established)<\/li><li>Repaglinide (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (established)<\/li><\/ul>"},{"id":"924104-s-4-15","title":"Moderate","mono":"<ul><li>Aluminum Carbonate, Basic (probable)<\/li><li>Aluminum Hydroxide (probable)<\/li><li>Aluminum Phosphate (probable)<\/li><li>Betamethasone (established)<\/li><li>Budesonide (established)<\/li><li>Calcium (probable)<\/li><li>Corticotropin (established)<\/li><li>Cortisone (established)<\/li><li>Cosyntropin (established)<\/li><li>Deflazacort (established)<\/li><li>Dexamethasone (established)<\/li><li>Dihydroxyaluminum Aminoacetate (probable)<\/li><li>Dihydroxyaluminum Sodium Carbonate (probable)<\/li><li>Fludrocortisone (established)<\/li><li>Fluocortolone (established)<\/li><li>Hydrocortisone (established)<\/li><li>Iron (probable)<\/li><li>Lanthanum Carbonate (probable)<\/li><li>Magaldrate (probable)<\/li><li>Magnesium Carbonate (probable)<\/li><li>Magnesium Hydroxide (probable)<\/li><li>Magnesium Oxide (probable)<\/li><li>Magnesium Trisilicate (probable)<\/li><li>Methylprednisolone (established)<\/li><li>Prednisolone (established)<\/li><li>Prednisone (established)<\/li><li>Triamcinolone (established)<\/li><\/ul>"}]},{"id":"924104-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (ophthalmic, 1% to 2%; oral or intravenous, 5%), Nausea (ophthalmic, 1% to 2%; oral or intravenous, 7%)<\/li><li><b>Neurologic:<\/b>Dizziness (3%), Headache (ophthalmic, 8% to 10%; oral or intravenous, 6%), Insomnia (4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (0.1% to 1%), Prolonged QT interval, Torsades de pointes, Ventricular tachycardia (0.1% to 1%)<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome<\/li><li><b>Endocrine metabolic:<\/b>Hypoglycemia (0.1% to 1%)<\/li><li><b>Hematologic:<\/b>Aplastic anemia, Pancytopenia, Thrombocytopenic purpura<\/li><li><b>Hepatic:<\/b>Hepatitis, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Hypersensitivity reaction (0.1% to 1%)<\/li><li><b>Musculoskeletal:<\/b>Myasthenia gravis, Exacerbation, Rupture of tendon, Tendinitis (0.1% to 1%)<\/li><li><b>Neurologic:<\/b>Peripheral neuropathy, Seizure (0.1% to 1%)<\/li><li><b>Ophthalmic:<\/b>Retinal detachment<\/li><li><b>Renal:<\/b>Acute renal failure (0.1% to 1%)<\/li><\/ul>"},{"id":"924104-s-6","title":"Drug Name Info","sub":{"0":{"id":"924104-s-6-17","title":"US Trade Names","mono":"<ul><li>Levaquin<\/li><li>Quixin<\/li><li>Iquix<\/li><\/ul>"},"2":{"id":"924104-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Fluoroquinolone<\/li><\/ul>"},"3":{"id":"924104-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924104-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"924104-s-7","title":"Mechanism Of Action","mono":"<ul><li>Ophthalmic: Levofloxacin's bactericidal action results from interference with the enzymes topoisomerase IV and DNA gyrase, which are needed for the synthesis of bacterial DNA.<\/li><li>Systemic: Levofloxacin acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, transcription, repair, and recombination .<\/li><\/ul>"},{"id":"924104-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924104-s-8-23","title":"Absorption","mono":"<ul><li>Systemic: Rapidly absorbed;<\/li><li>Bioavailability: 99%; food no affect<\/li><\/ul>"},"1":{"id":"924104-s-8-24","title":"Distribution","mono":"Systemic: Vd: 89 to 112 L <br\/>"},"3":{"id":"924104-s-8-26","title":"Excretion","mono":"Systemic: Fecal: 4%; Renal: 87% <br\/>"},"4":{"id":"924104-s-8-27","title":"Elimination Half Life","mono":"Systemic: 6 to 8 h <br\/>"}}},{"id":"924104-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>adequately hydrate patients to avoid concentrated urine and the development of crystalluria or cylindruria<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>oral and intravenous routes are interchangeable; therapy can be started with or changed, with the same dose and duration as soon as clinically appropriate.<\/li><li>do not give as IM, subQ, intrathecal, or intraperitoneal injection<\/li><li>dilute single-use vials of concentrated solution to final concentration of 5 mg\/mL; final volume of 250 mg dose should be 50 mL, infuse over 60 min; final volume of 500 mg dose should be 100 mL, infuse over 60 min; final volume of 750 mg dose should be 150 mL, infuse over 90 min<\/li><li>do not give as rapid or bolus infusion<\/li><\/ul><\/li><li><b>Ophthalmic<\/b><br\/>ophthalmic solutions should NOT be  injected subconjunctivally or introduced directly into the anterior chamber of the eye<br\/><\/li><li><b>Oral<\/b><br\/><ul><li>oral and intravenous routes are interchangeable; therapy can be started with or changed, with the same dose and duration as soon as clinically appropriate.<\/li><li>(tablet) take with or without food<\/li><li>(solution) take 1 hour before or 2 hours after food<\/li><li> take at least 2 hours before or 2 hours after sucralfate, metal cations such as iron, multivitamins with zinc, antacids containing aluminum or magnesium, or didanosine buffered tablets or powder for oral solution<\/li><\/ul><\/li><\/ul>"},{"id":"924104-s-10","title":"Monitoring","mono":"fever, CBC, symptomatic improvement<br\/>"},{"id":"924104-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Solution: 25 MG\/ML<\/li><li>Ophthalmic Solution: 0.5 %<\/li><li>Oral Solution: 25 MG\/ML, 500 MG\/20 ML, 250 MG\/10 ML<\/li><li>Oral Syrup: 25 MG\/ML<\/li><li>Oral Tablet: 250 MG, 500 MG, 750 MG<\/li><\/ul><\/li><li><b>Levaquin<\/b><br\/><ul><li>Intravenous Solution: 5 MG\/ML<\/li><li>Oral Solution: 25 MG\/ML<\/li><li>Oral Tablet: 250 MG, 500 MG, 750 MG<\/li><\/ul><\/li><li><b>Levaquin Leva-pak<\/b><br\/>Oral Tablet: 750 MG<br\/><\/li><li><b>Quixin<\/b><br\/>Ophthalmic Solution: 0.5 %<br\/><\/li><\/ul>"},{"id":"924104-s-12","title":"Toxicology","sub":[{"id":"924104-s-12-31","title":"Clinical Effects","mono":"<b>FLUOROQUINOLONES<\/b><br\/>USES: Fluoroquinolones are bacteriocidal broad spectrum antibiotics. PHARMACOLOGY: Fluoroquinolones inhibit bacterial topoisomerase IV and DNA gyrase enzymes required for DNA replication, transcription, repair and recombination. EPIDEMIOLOGY: Overdose is rare. OVERDOSE: Dizziness, drowsiness, disorientation, slurred speech, nausea and vomiting. ADVERSE EFFECTS: Nausea\/vomiting, diarrhea, headache, drowsiness, and insomnia. Seizures, hallucinations, elevated liver enzymes and renal toxicity are rare. Seizures appear related to predisposing factors. Hypersensitivity reactions including anaphylaxis and vasculitis have developed. WITHDRAWAL FROM MARKET: Grepafloxacin was withdrawn from the worldwide market in October, 1999 after reports of cardiovascular toxicity; QT prolongation had been associated with its use. Gatifloxacin was voluntarily withdrawn from the market in May 2006 due to reports of severe hypo- and hyperglycemic events. <br\/>"},{"id":"924104-s-12-32","title":"Treatment","mono":"<b>FLUOROQUINOLONES <\/b><br\/><ul><li>Support: Treatment is symptomatic and supportive.<\/li><li>Decontamination: Activated charcoal, gastric lavage<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Monitoring of patient: Monitor liver enzymes and renal function with significant overdose.  Monitor fluid &amp; electrolyte status if severe GI effects; CNS function.<\/li><\/ul>"},{"id":"924104-s-12-33","title":"Range of Toxicity","mono":"<b>FLUOROQUINOLONES<\/b><br\/>Unknown.  Recommended dose (adults):  300-500 mg BID; contraindicated in children. <br\/>"}]},{"id":"924104-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to immediately report symptoms of tendonitis or tendon rupture (pain, swelling, inflammation of tendon), especially if elderly and\/or using concomitant steroids.<\/li><li>Tell patient to immediately report symptoms of peripheral neuropathy, including pain, burning, tingling, or numbness.<\/li><li>Advise patient to avoid tanning beds and to use sunscreen, protective clothing, and hats, as drug is phototoxic.<\/li><li>Tell patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness or lightheadedness.<\/li><li>Side effects may include constipation, nausea, taste disturbance, headaches, insomnia, convulsions, toxic psychoses, and increased intracranial pressure, including pseudotumor cerebri.<\/li><li>Ophthalmic side effects may include decreased or blurred vision.<\/li><li>Advise patient to report symptoms of QT prolongation (tachycardia, loss of consciousness) or persistent diarrhea (bloody\/watery stools).<\/li><li>Tell patient to immediately report symptoms of hepatotoxicity, including anorexia, fever, muscle weakness, fatigue, pruritus, or jaundice.<\/li><li>Instruct diabetic patient to report symptoms of inadequate glycemic control and advise more frequent monitoring of blood glucose.<\/li><li>Advise patient to take oral solution 1 hour before or 2 hours after eating.<\/li><li>Instruct patient to take oral drug at the same time each day with plenty of fluids to prevent concentrated urine and crystal formation.<\/li><li>Instruct patient to take oral drug 2 hours before or 2 hours after magnesium or aluminum-containing antacids, sucralfate, didanosine (buffered tablets or powder for oral solution), or products containing iron or zinc.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use, including over-the-counter and herbal drugs.<\/li><\/ul>"}]}